NY-THE-BODY-SHOP
9.1.2023 07:16:30 CET | Business Wire | Press release
Today is No Say Day - the last day in 2023 when young people’s voices are represented in parliaments around the world. This falls a week before world leaders and businesses gather in Davos for the World Economic Forum Annual Meeting. Often criticised for being out of touch, Davos is a prime example of the need for more youth voices in decision making spaces.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230108005001/en/
Antonia Tony-Fadipe, Inclusive Hiring Lead and The Body Shop Youth Collective member; Urvasi De Biasi, Activism Policy and Partnerships, The Body Shop; Lily Cannon, Activism Communications Manager, The Body Shop; Lucila San Martin, Global Activism Manager, The Body Shop (Photo: Business Wire)
Half of the world’s population is under 30, compared to just 2.6% of parliamentarians globally*. If this ratio were reflected in a year, youth voices would effectively go unheard after today. Just nine days into 2023, No Say Day is a stark demonstration of the fact that millions of young voices are excluded from decision-making spaces at a time when the world is facing extreme systemic challenges.
No Say Day is being marked as part of the Be Seen Be Heard campaign, led by The Body Shop in collaboration with the Office of the United Nations Secretary-General's Envoy on Youth to raise the voices of millions of young people in over 75 countries across six continents.
Public opinion is widely in favour of fairer political representation for young people. According to The Body Shop’s largest-ever global survey**, two thirds of people agree that the age balance in politics is wrong.
People across all age groups agree that political systems would be improved by giving young people a say in policy development. Young people are optimistic and determined to increase their involvement in public life. A third of those under age 30 surveyed would consider running for office, versus only a fifth of those over age 30.
Chris Davis, Global Sustainability and Activism Director at The Body Shop, said: “From climate change to economic instability and conflict, the world’s problems are too great to fall back on business-as-usual. Young people are energetic, thoughtful, and positive about the future – so it’s important their voices are seen and heard in parliaments around the world every day. This is clearly the preference of the public, who support a fairer approach to youth representation and trust young people’s views on the major issues of today.
“As world leaders and captains of industry gather in Davos next week, I urge them to work with young people to develop solutions to the problems we all face. Let’s make today the last No Say Day in our history.”
Jayathma Wickramanayake, the UN Secretary-General’s Envoy on Youth, said: “Young people are the experts of their own realities, and young people all over the world are making a difference every day by tackling issues that matter most to them. The idea that young people are change makers is not just a marketing campaign, it is a fact. We must dispel the myths surrounding young people, that they are irresponsible, disengaged, troublemakers, or do not have the experience to create real impact. Even in the most adverse of circumstances we have seen young people rising to the challenge and leading the way — from humanitarian crises to COVID-19 response. There is no doubt that we need young people’s innovation, drive, creativity and – more than anything – unwavering optimism that a better world is possible for everyone.”
ENDS
*https://www.ipu.org/our-impact/youth-empowerment/data-youth-participation
**The Be Seen Be Heard Global Youth Survey
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230108005001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
